



41

Atty. Dkt. No. 028622-0101

Image  
1642  
#  
1**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Achim Dickmanns et al.  
Title: IMMORTALIZED EPITHELIAL TUMOR CELLS  
Appl. No.: 08/981,583  
Filing Date: 02/03/1998  
Examiner: Alana M. Harris  
Art Unit: 1642

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.56**

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.113, or an action that otherwise closes prosecution in the application.

11/04/2003 ZJUHAR1 00000057 08981583

01 FC:1806

180.00 0P

002.1099000.1

**RELEVANCE OF EACH DOCUMENT**

The relevance of the foreign-language documents is described in the present specification. An English translation of the foreign-language documents is not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language documents (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

**FEE**

A fee in connection with submission of an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date November 3, 2003

By Jayme A. Huleatt

FOLEY & LARDNER  
Customer Number: 22428  
Telephone: (202) 672-5542  
Facsimile: (202) 672-5399

Jayme A. Huleatt  
Attorney for Applicant  
Registration No. 34,485

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: November 3, 2003 (use as many sheets as necessary)				<b>Complete if Known</b>													
NOV 03 2003 PCT/US03/03480 O P E INFORMATION DISCLOSURE STATEMENT BY APPLICANT 1 of 2		<table border="1"> <tr> <td><b>Application Number</b></td> <td>08/981,583</td> </tr> <tr> <td><b>Filing Date</b></td> <td>02/03/1998</td> </tr> <tr> <td><b>First Name &amp; Inventor</b></td> <td>Achim Dickmanns</td> </tr> <tr> <td><b>Group Art Unit</b></td> <td>1642</td> </tr> <tr> <td><b>Examiner Name</b></td> <td>Alana M. Harris</td> </tr> <tr> <td><b>Attorney Docket Number</b></td> <td>028622-0101</td> </tr> </table>				<b>Application Number</b>	08/981,583	<b>Filing Date</b>	02/03/1998	<b>First Name &amp; Inventor</b>	Achim Dickmanns	<b>Group Art Unit</b>	1642	<b>Examiner Name</b>	Alana M. Harris	<b>Attorney Docket Number</b>	028622-0101
<b>Application Number</b>	08/981,583																
<b>Filing Date</b>	02/03/1998																
<b>First Name &amp; Inventor</b>	Achim Dickmanns																
<b>Group Art Unit</b>	1642																
<b>Examiner Name</b>	Alana M. Harris																
<b>Attorney Docket Number</b>	028622-0101																

<b>FOREIGN PATENT DOCUMENTS</b>								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
A1	DE	42 28 389	C2	Kubler et al.	Kubler et al.	07-21-1994		
A2	DE	43 22 570	C1	Thalmeier et al.	Thalmeier et al.	06-16-1994		
A3	DE	44 22 570	C2	Gleich Patentinhaber	Gleich Patentinhaber	09-04-1997		
A4	EP	0 256 512	B1	Willecke et al.	Willecke et al.	09-31-1993		

<b>NON PATENT LITERATURE DOCUMENTS</b>								
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>6</sup>	
	A5	Ariyoshi et al., "Biological and Clinical Implication of Neuron-Specific Enolase and Creatine Kinase BB in Small Cell Lung Cancer," <i>Jpn. J. Clin. Oncol.</i> 16(3):213-221 (1986).						
	A6	Chen et al., "Detection of Bone Marrow Micrometastasis," <i>Hybridoma</i> 18(5):465-466 (1999) © Mary Ann Liebert, Inc.						
	A7	Bartek et al., "Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus," <i>Proc. Natl. Acad. Sci USA</i> , 88:3520-3524 (May 1991) ©Cell Biology.						
	A8	Bepler et al., "Markers and characteristics of human SCLC cell lines," <i>J. Cancer Res. Clin. Oncol.</i> 113:253-259 (1987) ©Springer-Verlag.						
	A9	Bonfil et al., "Invasive and Metastatic Potential of a v-Ha-ras-Transformed Human Bronchial Epithelial Cell Line," <i>Journal of the National Cancer Institute</i> 81(8):587-594 (April 19, 1989)						
	A10	Carney et al., "Establishment and Identification of Small Cell Lung Cancer Cell Lines Having Classic and Variant Features," <i>Cancer Research</i> 45:2913-2923 (June 1985)						
	A11	Gazdar, Adi F. "The Molecular and Cellular Basis of Human Lung Cancer," <i>Anticancer Research</i> 13:261-268 (1994).						
	A12	Giaccone et al., "Neuromedin B Is Present in Lung Cancer Cell Lines," <i>Cancer Research</i> (Suppl) S2:2732s-2736s (May 1, 1992).						
	A13	Krahenbuhl, J.P., "Dispersed Mammary Gland Epithelial Cells," <i>The Journal of Cell Biology</i> 72:390-405 (1977).						
	A14	Lebacq-Verheyden, et al. "Posttranslational Processing of Endogenous and of Baculovirus-Expressed Human Gastrin-Releasing Peptide Precursor," <i>Molecular and Cellular Biology</i> , 8(8): 3129-3135 (Aug. 1988). © American Society for Microbiology.						

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>C mplete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	08/981,583
NOV 03 2003 Date Submitted: November 3, 2003 (use as many sheets as necessary)				<b>Filing Date</b>	02/03/1998
		2      of      2		<b>First Named Inventor</b>	Achim Dickmanns
				<b>Group Art Unit</b>	1642
				<b>Examiner Name</b>	Alana M. Harris
				<b>Attorney Docket Number</b>	028622-0101

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A15	Minna et al., "Cancer of the Lung," <i>Cancer Principles &amp; Practice of Oncology</i> , Fifth Edition, edited by DeVita et al., Chapter 30 pages 849-912 (1997)	
	A16	Mountain, M.D., Clifton F. "The New International Staging System for Lung Cancer," <i>Surgical Treatment of Lung Carcinoma</i> , 67(5): 925-935 (October 1987).	
	A17	Riquet et al., "Factors determining survival in resected N2 lung cancer," <i>Eur. J. Cardio-thorac Surg.</i> 9:300-304 (1995) © Springer-Verlag.	
	A18	Roth et al., "A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer," <i>Journal of the National Cancer Institute</i> 86(9): 673-680 (May 4, 1994)	
	A19	Shimosato, et al., "Biological, Pathological and Clinical Features of Small Cell Lung Cancer," <i>Cancer Letters</i> 33:241-258 (1986) © Elsevier Scientific Publishers Ireland Ltd.	
	A20	Thorban et al., "Disseminated Epithelial Tumor Cells in Bone Marrow of Patients with Esophageal Cancer: Detection and Prognostic Significance," <i>World Journal of Surgery</i> 20: 567-573 (1996) © Societe Internationale de Chirurgie.	
	A21	Yanagihara, et al., "A Radiation-induced Murine Ovarian Granulosa Cell Tumor Line: Introduction of v-ras Gene Potentiates a High Metastatic Ability," <i>Japan J. Cancer Res.</i> , 86:346-356 (April 1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.